The Technical Field "腫瘍" had 65 patent application filings in the most recent period (2023-01-01 to 2023-04-30). This is a significantly decreased of -930 filings (-93.5%) over 995 they had in the same period of the previous year (2022-01-01 to 2022-04-30). This report also includes technical terms related to " 新生物 ", " 腫よう ", " しゅよう " in the search set.
The highest number of filings in 2019 with 3,879 cases, and their lowest number in 2023 with 119 cases.
The mean of the number of filings over the last 5 years (2019 to 2024, 13,052 cases in total) is 2,175, and the median is 2,924. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
Index | Value |
---|---|
Average | 2,175 patents |
Std Dev | 1,526 |
COV | 0.7 |
Year | Cases | YOY |
---|---|---|
2023 year | 119 cases | -95.8 % |
2022 year | 2,809 cases | -7.54 % |
2021 year | 3,038 cases | -4.82 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for 腫瘍 for the period of the last 10 years (2015-01-01 to 2024-12-31). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of 腫瘍, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
The changes in the number of patent filings of 腫瘍 over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
This patent analysis report was created for a patent search set of 27,303 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 腫瘍 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Comparing the number of applications of each company, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last in the last 3 years (2023 to 2025) with 2 cases.
Name | Cases |
---|---|
ジェネンテックインコーポレイテッド | 2 cases |
Comparing the number of applications of each company, ノバルティスアーゲー has the highest number of joint applications in the last for the target period (2015 to 2025) with 396 cases, followed by ジェネンテックインコーポレイテッド with 357 cases.
Name | Cases |
---|---|
ノバルティスアーゲー | 396 cases |
ジェネンテックインコーポレイテッド | 357 cases |
ブリストル-マイヤーズスクイブカンパニー | 262 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 239 cases |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 208 cases |
ボードオブリージェンツザユニバーシティオブテキサスシステム | 179 cases |
メルクパテントゲゼルシャフトミットベシュレンクテルハフツング | 111 cases |
ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 99 cases |
エフホフマン-ラロシュアーゲー | 85 cases |
アメリカ合衆国 | 55 cases |
武田薬品工業株式会社 | 54 cases |
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 腫瘍 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Among the top coapplicants, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last in the last 3 years (2023 to 2025) with 2 cases.
Name | Cases |
---|---|
ジェネンテックインコーポレイテッド | 2 cases |
Among the top coapplicants, ノバルティスアーゲー has the highest number of joint applications in the last for the target period (2015 to 2025) with 396 cases, followed by ジェネンテックインコーポレイテッド with 357 cases.
Name | Cases |
---|---|
ノバルティスアーゲー | 396 cases |
ジェネンテックインコーポレイテッド | 357 cases |
ブリストル-マイヤーズスクイブカンパニー | 262 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 239 cases |
メルクパテントゲゼルシャフトミットベシュレンクテルハフツング | 111 cases |
エフホフマン-ラロシュアーゲー | 85 cases |
アメリカ合衆国 | 55 cases |
Below is a ranking of the number of JP patent applications by 腫瘍’s top 7 coapplicants over the last 20 years.
Below is a patent map showing the changes in the numbers of JP patent filings by 腫瘍’s top 7 coapplicants over the last 20 years.
腫瘍 filed 396 joint applications with ノバルティスアーゲー for the analysis period (2015 to 2025).
The mean of the number of filings over the last 5 years (2019 to 2024, 131 cases in total) is 21.8, and the median is 23.0. The coefficient of variation (standard deviation/mean) is 0.8, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2021 to 2024). The highest number of filings in 2015 with 85 cases, and their lowest number in 2023 with 0 cases.
Index | Value |
---|---|
Average | 21.8 patents |
Std Dev | 17.9 |
COV | 0.8 |
Year | Cases | YOY |
---|---|---|
2022 year | 17 cases | -55.3 % |
2021 year | 38 cases | +31.0 % |
2020 year | 29 cases | -38.3 % |
腫瘍 filed 357 joint applications with ジェネンテックインコーポレイテッド for the analysis period (2015 to 2025).
The mean of the number of filings over the last 5 years (2019 to 2024, 141 cases in total) is 23.5, and the median is 29.0. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2015 with 82 cases, and their lowest number in 2023 with 2 cases.
Index | Value |
---|---|
Average | 23.5 patents |
Std Dev | 17.2 |
COV | 0.7 |
Year | Cases | YOY |
---|---|---|
2023 year | 2 cases | -94.6 % |
2022 year | 37 cases | -15.91 % |
2021 year | 44 cases | +100 % |
腫瘍 filed 111 joint applications with メルクパテントゲゼルシャフトミットベシュレンクテルハフツング for the analysis period (2015 to 2025).
The mean of the number of filings over the last 5 years (2019 to 2024, 38 cases in total) is 6.3, and the median is 7.5. The coefficient of variation (standard deviation/mean) is 0.8, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2015 with 25 cases, and their lowest number in 2023 with 0 cases.
Index | Value |
---|---|
Average | 6.3 patents |
Std Dev | 4.9 |
COV | 0.8 |
Year | Cases | YOY |
---|---|---|
2022 year | 10 cases | +25.00 % |
2021 year | 8 cases | -38.5 % |
2020 year | 13 cases | +85.7 % |
腫瘍 filed 85 joint applications with エフホフマン-ラロシュアーゲー for the analysis period (2015 to 2025).
The mean of the number of filings over the last 5 years (2019 to 2024, 36 cases in total) is 6.0, and the median is 4.5. The coefficient of variation (standard deviation/mean) is 1.0, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2017 with 25 cases, and their lowest number in 2023 with 0 cases.
Index | Value |
---|---|
Average | 6.0 patents |
Std Dev | 6.0 |
COV | 1.0 |
Year | Cases | YOY |
---|---|---|
2022 year | 5 cases | +25.00 % |
2021 year | 4 cases | -60.0 % |
2020 year | 10 cases | -41.2 % |
腫瘍 filed 239 joint applications with ザリージェンツオブザユニバーシティオブカリフォルニア for the analysis period (2015 to 2025).
The mean of the number of filings over the last 5 years (2019 to 2024, 112 cases in total) is 18.7, and the median is 25.0. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2016 with 42 cases, and their lowest number in 2023 with 0 cases.
Index | Value |
---|---|
Average | 18.7 patents |
Std Dev | 13.5 |
COV | 0.7 |
Year | Cases | YOY |
---|---|---|
2022 year | 27 cases | +17.39 % |
2021 year | 23 cases | -30.3 % |
2020 year | 33 cases | +13.79 % |
The following shows JP patents held by 腫瘍 that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and 腫瘍’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which 腫瘍 is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
In the last 3 years (2022-01-01 ~ 2024-12-31), there were 5 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 2.0 times. The most recently Invalidation Trial patent is 特許6445123 "癌を治療するための方法及び組成物" (Invalidation Trial day 2023-11-25) , next is 特許4110140 "チロシンキナーゼの阻害剤" (Invalidation Trial day 2023-08-10) .
- | No. | Title | Invalidation Trial days |
---|---|---|---|
1 | 特許6445123 | 癌を治療するための方法及び組成物 | 2023-11-25 |
2 | 特許4110140 | チロシンキナーゼの阻害剤 | 2023-08-10 |
3 | 特許5474043 | (+)−2−[1−(3−エトキシ−4−メトキシフェニル)−2−メチルスルホニルエチル]−4−アセチルアミノイソインドリン−1,3−ジオンを含む固形物形態、その組成物およびその使用 | 2023-05-31 |
4 | 特許7016341 | PD-1軸結合アンタゴニスト及びTIGIT阻害剤を使用するがんの治療方法 | 2023-03-27 |
5 | 特許6278598 | 細胞傷害誘導治療剤 | 2022-03-31 |
Of the patent applications filed in the last 10 years (2015-01-01 to 2024-12-31), 6 patents/patent applications were invalidation trial more than once in the examination process of other patent applications. The mean of the number of invalidation trial is 1.7. The most invalidation trial patent is 特許6445123 "癌を治療するための方法及び組成物" (5 times) , and the next most invalidation trial patent is 特許6466538 "治療薬のCNS送達" (1 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6445123 | 癌を治療するための方法及び組成物 | 5 times |
2 | 特許6466538 | 治療薬のCNS送達 | 1 times |
3 | 特許6258428 | 肺癌治療剤 | 1 times |
4 | 特許6074462 | 抗−TNFα抗体の投与方法 | 1 times |
5 | 特許6293103 | 自己緩衝タンパク質製剤 | 1 times |
In the last 3 years (2022-01-01 ~ 2024-12-31), there were 15 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7492459 "加齢に関連する状態の診断及び治療のための組成物及び方法" (Opposition day 2024-11-27) , next is 特許7475848 "細胞解析方法、細胞解析装置、細胞解析システム、及び細胞解析プログラム、並びに訓練された人工知能アルゴリズムの生成方法、生成装置、及び生成プログラム" (Opposition day 2024-10-15) .
- | No. | Title | Opposition days |
---|---|---|---|
1 | 特許7492459 | 加齢に関連する状態の診断及び治療のための組成物及び方法 | 2024-11-27 |
2 | 特許7475848 | 細胞解析方法、細胞解析装置、細胞解析システム、及び細胞解析プログラム、並びに訓練された人工知能アルゴリズムの生成方法、生成装置、及び生成プログラム | 2024-10-15 |
3 | 特許7344565 | 未分化細胞検出法 | 2024-03-13 |
4 | 特許7325924 | 医用画像処理装置、その制御方法、及びプログラム | 2024-02-01 |
5 | 特許7298844 | 細胞培養物の製造方法 | 2023-12-26 |
6 | 特許7244922 | 化学修飾された一本鎖RNA編集オリゴヌクレオチド | 2023-09-20 |
7 | 特許7237544 | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 | 2023-09-11 |
8 | 特許7217589 | 画像解析方法、画像解析装置、プログラム、学習済み深層学習アルゴリズムの製造方法および学習済み深層学習アルゴリズム | 2023-08-03 |
9 | 特許7074345 | 一本鎖RNA編集オリゴヌクレオチド | 2022-11-18 |
10 | 特許7060510 | 腫瘍マーカーの測定方法及び測定試薬 | 2022-10-26 |
In the last 3 years (2022-01-01 ~ 2024-12-31), there were 41 patents Protest from third parties. The average number of Protest is 1.2 times. The most recently Protest patent is 特表2023-510911 "卵巣癌を検出するための組成物及び方法" (Protest day 2024-10-11) , next is 特表2023-542536 "オリゴ糖組成物及び使用方法" (Protest day 2024-10-09) .
- | No. | Title | Protest days |
---|---|---|---|
1 | 特表2023-510911 | 卵巣癌を検出するための組成物及び方法 | 2024-10-11 |
2 | 特表2023-542536 | オリゴ糖組成物及び使用方法 | 2024-10-09 |
3 | 特表2024-508601 | 多層経口薄フィルム | 2024-07-26 |
4 | 特開2024-038396 | 画像解析方法、画像解析装置、およびプログラム | 2024-07-16 |
5 | 特開2022-028813 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 | 2024-05-02 |
6 | 特許7527978 | カンプトテシンコンジュゲート | 2024-03-25 |
7 | 特許7479635 | γδT細胞の製造方法 | 2024-02-19 |
8 | 特表2023-544184 | 接着細胞からのウイルスのバイオリアクター生成 | 2024-02-01 |
9 | 特表2021-506842 | ポリペプチドの放射性標識 | 2024-01-31 |
10 | 特開2023-052609 | 細胞培養物の製造方法 | 2024-01-23 |
11 | 特表2021-500373 | 線維芽細胞活性化タンパク質α(FAP−α)を標的とする撮像剤および放射線療法用薬剤 | 2024-01-12 |
12 | 特開2022-130629 | ベンダムスチンの製剤 | 2023-09-29 |
13 | 特開2022-141895 | ベンダムスチンの製剤 | 2023-09-29 |
14 | 特開2021-162323 | 疾患鑑別支援方法、疾患鑑別支援装置、及び疾患鑑別支援コンピュータプログラム | 2023-09-01 |
15 | 特開2023-053140 | チェックポイント遮断およびマイクロサテライト不安定性 | 2023-07-27 |
16 | 再公表2019/189882 | NCC−ST−439抗原と特異的に反応するモノクローナル抗体およびその製造方法。 | 2023-07-20 |
17 | 特許7507209 | がんを治療するための、PD-1アンタゴニスト及びVEGFR/FGFR/RETチロシンキナーゼ阻害剤の組合せ | 2023-07-12 |
18 | 特開2023-036582 | がんのための治療方法及び診断方法 | 2023-06-26 |
19 | 特許7568698 | 難治性ホジキンリンパ腫におけるニボルマブでのPD-1遮断 | 2023-04-27 |
20 | 特表2021-504096 | 活性化表面に結合した接着層 | 2023-03-23 |
Of the patent applications filed in the last 10 years (2015-01-01 to 2024-12-31), 70 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.2. The most protest patent is 特許6904707 "ヒト化プログラム細胞死1遺伝子を持つ非ヒト動物" (3 times) , and the next most protest patent is 特表2021-524495 "酸化的ストレスおよびミトコンドリアストレスから,細胞を保護する組成物" (3 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6904707 | ヒト化プログラム細胞死1遺伝子を持つ非ヒト動物 | 3 times |
2 | 特表2021-524495 | 酸化的ストレスおよびミトコンドリアストレスから,細胞を保護する組成物 | 3 times |
3 | 特許7479635 | γδT細胞の製造方法 | 2 times |
4 | 特開2016-166173 | PD−1、B7−4の受容体、およびその使用 | 2 times |
5 | 特許7217589 | 画像解析方法、画像解析装置、プログラム、学習済み深層学習アルゴリズムの製造方法および学習済み深層学習アルゴリズム | 2 times |
In the last 3 years (2022-01-01 ~ 2024-12-31), there were 477 patents Inspection from third parties. The average number of Inspection is 1.3 times. The most recently Inspection patent is 特表2023-510211 "抗NKp30抗体及び使用方法" (Inspection day 2024-12-27) , next is 特表2022-512593 "抗原提示細胞の機能を増強するための生体分子の細胞内送達" (Inspection day 2024-12-19) .
- | No. | Title | Inspection days |
---|---|---|---|
1 | 特表2023-510211 | 抗NKp30抗体及び使用方法 | 2024-12-27 |
2 | 特表2022-512593 | 抗原提示細胞の機能を増強するための生体分子の細胞内送達 | 2024-12-19 |
3 | 特表2024-502755 | がんを処置する方法 | 2024-12-18 |
4 | 特表2024-500877 | がんを処置する方法 | 2024-12-18 |
5 | 特表2024-500874 | がんを処置する方法 | 2024-12-18 |
6 | 特表2024-504002 | がんを処置する方法 | 2024-12-18 |
7 | 特表2022-513062 | B細胞悪性腫瘍を処置するために、操作されたT細胞を投薬する方法 | 2024-12-10 |
8 | 特開2023-062063 | 抗KIT抗体及びその使用 | 2024-12-10 |
9 | 特表2022-516496 | キメラ受容体ポリペプチド及びその使用 | 2024-12-10 |
10 | 特表2022-522775 | LILRB4結合抗体およびその使用方法 | 2024-12-10 |
11 | 特表2022-532564 | 先駆制御性細胞栄養芽細胞およびその使用 | 2024-12-10 |
12 | 特表2021-519758 | LFA3バリアントならびにその組成物および使用法 | 2024-12-06 |
13 | 特表2021-525549 | 腫瘍特異的ネオ抗原およびその使用方法 | 2024-12-04 |
14 | 特許7600282 | 5′-アデノシン二リン酸リボース(ADPR)の使用方法 | 2024-11-27 |
15 | 特表2022-547154 | 調節可能な制御のためのCA2-IL15融合タンパク質 | 2024-11-25 |
16 | 特表2021-525595 | 薄型多剤注入システムおよび方法 | 2024-11-22 |
17 | 特表2022-516318 | カプセル化ポリヌクレオチド及び使用方法 | 2024-11-22 |
18 | 特表2022-514116 | 新規な癌抗原及び方法 | 2024-11-21 |
19 | 特開2022-097486 | mRNAの機能状態を変化させてその選択的かつ特異的な認識を可能にする方法 | 2024-11-14 |
20 | 特表2024-512769 | 抗原特異的T細胞を生成し、疾患を治療するための材料及び方法 | 2024-11-06 |
Of the patent applications filed in the last 10 years (2015-01-01 to 2024-12-31), 902 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.3. The most inspection patent is 特許6320473 "アロNKT細胞を用いた免疫療法およびそのためのT細胞抗原受容体(TCR)遺伝子のα鎖領域が均一なVα−Jαに再構成されている細胞および該細胞由来NKT細胞のバンキング" (48 times) , and the next most inspection patent is 特開2017-214435 "抗CD20抗体の投与を含むB細胞リンパ腫の併用療法" (43 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6320473 | アロNKT細胞を用いた免疫療法およびそのためのT細胞抗原受容体(TCR)遺伝子のα鎖領域が均一なVα−Jαに再構成されている細胞および該細胞由来NKT細胞のバンキング | 48 times |
2 | 特開2017-214435 | 抗CD20抗体の投与を含むB細胞リンパ腫の併用療法 | 43 times |
3 | 特許6241794 | 抗CD20抗体の投与を含むB細胞リンパ腫の併用療法 | 9 times |
4 | 特許6445123 | 癌を治療するための方法及び組成物 | 8 times |
5 | 特表2021-524495 | 酸化的ストレスおよびミトコンドリアストレスから,細胞を保護する組成物 | 8 times |
Of the patent applications filed in the last 10 years (2015-01-01 to 2024-12-31), 4,137 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.3. The most cited patent is 特許6594901 "パルス電界を使用した細胞の細胞内効果の選択的調節" (52 times) , and the next most cited patent is 特許7051188 "パルス電界を使用した細胞の細胞内効果の選択的調節" (43 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6594901 | パルス電界を使用した細胞の細胞内効果の選択的調節 | 52 times |
2 | 特許7051188 | パルス電界を使用した細胞の細胞内効果の選択的調節 | 43 times |
3 | 特許6778114 | イミド系タンパク質分解モジュレーター及び関連する使用方法 | 36 times |
4 | 特許6716586 | FGFR4阻害剤としての二環式複素環 | 31 times |
5 | 特表2019-526851 | 分散型機械学習システム、装置、および方法 | 29 times |
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
All rights to the data, documents, figures and tables are reserved by e-Patent. When publishing internal documents, external reports, etc. (whether paid or free of charge), please use the following URL: https://e-patent.co.jp/.
e-Patent will not be liable for any damages or losses arising from the use of the global patent application status, ranking information, or population search formula in the "SDGs Global Company Ranking from a Patent Perspective". Items with ● in front of the target are not supported at this time (judged to be difficult to approach from the patent information analysis).
There is no problem to cite patent application status and ranking information, but please clearly indicate "Source: e-Patent Co.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International